AZothBio

AZothBio is a South Korea-based private biotech company focused on AI-enabled drug discovery and drug delivery. The company integrates artificial intelligence modules for molecular design, kinase activity prediction, peptide analysis, and delivery optimization to discover first-in-class and best-in-class therapeutics. Its disclosed internal pipeline includes AZB-101, a selective allosteric TYK2-JH2 small-molecule inhibitor for autoimmune and inflammatory diseases, and the company has also described work in NTRK-targeted oncology and cell-penetrating peptide technologies. AZothBio positions itself as both a platform company and a developer of proprietary therapeutic programs, with collaborations spanning precision medicine, academic medical centers, and Korean drug-development infrastructure.